Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06664853 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension of EryDex Study IEDAT-04-2022
A Phase 3 study, sponsored by Quince Therapeutics S.p.A..
- Terminated
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
NCT06664853: Clinical Trial Phase 3 study, sponsored by Quince Therapeutics S.p.A..
NCT06664853 is a Phase 3 study that was terminated before completion, run by Quince Therapeutics S.p.A.. The registered enrollment target is 101 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06664853, a Phase 3 study, was terminated before completion, sponsored by Quince Therapeutics S.p.A..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
Study Summary
This is an international, multi-center, prospective, open-label, non-comparative study aiming to provide access to treatment with EryDex to ataxia telangiectasia (A-T) patients who completed the IEDAT-04-2022 trial which studied the neurological effects of EryDex on subjects with ataxia telangiectasia (NEAT trial).
Interventions
- DRUG Dexamethasone sodium phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2024-12-11 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06664853
The ClinicalTrials.gov registry entry for NCT06664853 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quince Therapeutics S.p.A., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dexamethasone sodium phosphate is the first listed.
NCT06664853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06664853 about?
NCT06664853 is a clinical study titled "Open-Label Extension of EryDex Study IEDAT-04-2022". This is an international, multi-center, prospective, open-label, non-comparative study aiming to provide access to treatment with EryDex to ataxia telangiectasia (A-T) patients who completed the IEDAT-04-2022 trial which studied the neurological effects of EryDex on subjects with ataxia telangiectas...
What is the current status of trial NCT06664853?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2024-12-11. Estimated completion is 2026-01-30.
What interventions are being tested in trial NCT06664853?
The interventions under investigation include: Dexamethasone sodium phosphate (DRUG).
Who is sponsoring clinical trial NCT06664853?
This trial is sponsored by Quince Therapeutics S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.